Adalimumab appears to be more effective than thiopurines for preventing Crohn’s disease recurrence after ileocecal resection, according to early results from the first trial prospectively comparing the two therapies.
When completed, the POCER trial – of which this data is a part – will be the largest gastroenterological trial ever conducted in Australia. It is hoped the trial will provide an algorithm allowing clinicians to risk-stratify patients according to who is most likely to go on to experience recurrence and assess the utility of step-up therapy in those patients.
In the current data, only high-risk patients who did not tolerate azathioprine were given adalimumab as a replacement. Six months into the trial, the Australian authors presented mucosal recurrence data on 45 patients...
This site is intended for Registered Medical Practitioners.
To make the most of Gastroenterology Update, you need to be logged in.